摘要
背景:溶瘤病毒例如活减毒的麻疹病毒(MV)疫苗株最近已经作为有希望的癌症治疗剂出现,已经显示出对大量人肿瘤的显著的抗肿瘤活性。 目的:我们的研究旨在确定哪些参数定义人黑素瘤细胞对溶瘤性MV感染的敏感性。 方法:我们在体外和体内分析MV对在我们实验室中建立的一组人黑素瘤细胞的溶瘤活性。我们测试了I型干扰素或干扰素途径抑制剂Ruxolitinib是否可以调节这些细胞对溶瘤性MV感染的敏感性。 结果:人黑色素瘤细胞对培养物中和作为肿瘤异种移植物的MV感染表现出不同水平的敏感性。因为这些差异不是由它们的CD46受体的表达水平解释的,所以我们假设抗病毒免疫应答可能在某些细胞中被抑制,导致它们不能有效地控制感染。通过分析I型IFN应答,我们发现抗性细胞具有在MV感染时被激活的完全功能性途径。相反,敏感的细胞在这个途径中显示缺陷。当用IFN-α和IFN-β预处理时,除一个敏感细胞外的所有细胞都变得对MV耐受。使用Ruxolitinib对MV耐受的细胞对MV敏感。结论:I型干扰素反应是黑素瘤对溶瘤性MV感染的敏感性或抗性的主要决定因素。这将在未来的溶瘤性MV临床试验中考虑。
关键词: 黑素瘤,干扰素,麻疹病毒,溶瘤,癌症病毒疗法,Ruxolitinib
Current Gene Therapy
Title:Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Volume: 16 Issue: 6
关键词: 黑素瘤,干扰素,麻疹病毒,溶瘤,癌症病毒疗法,Ruxolitinib
摘要: Background: Oncolytic viruses such as live-attenuated, vaccine strains of measles virus (MV) have recently emerged as promising cancer treatments, having shown significant antitumor activity against a large variety of human tumors.
Objective: Our study aims at determining which parameters define the sensitivity of human melanoma cells to oncolytic MV infection.
Methods: We analyzed both in vitro and in vivo the oncolytic activity of MV against a panel of human melanoma cell established in our laboratory. We tested whether either type I interferons or the interferon pathway inhibitor Ruxolitinib could modulate the sensitivity of these cells to oncolytic MV infection.
Results: Human melanoma cells exhibit varying levels of sensitivity to MV infection in culture and as tumor xenografts. As these differences are not explained by their expression level of the CD46 receptor, we hypothesized that antiviral immune responses may be suppressed in certain cell resulting in their inability to control infection efficiently. By analyzing the type I IFN response, we found that resistant cells had a fully functional pathway that was activated upon MV infection. On the contrary, sensitive cell showed defects in this pathway. When pre-treated with IFN-α and IFN-β, all but one of the sensitive cell became resistant to MV. Cells resistant to MV were rendered sensitive to MV with Ruxolitinib. Conclusion: Type I interferon response is the main determinant for the sensitivity or resistance of melanoma to oncolytic MV infection. This will have to be taken into account for future clinical trials on oncolytic MV.
Export Options
About this article
Cite this article as:
Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170102110502
DOI https://dx.doi.org/10.2174/1566523217666170102110502 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Small Molecule Inhibitor of FAK and IGF-1R Protein Interactions Decreases Growth of Human Esophageal Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Action of DNA-Damaging Anticancer Drugs in Treatment of Carcinomas: Is Acute Apoptosis an “Off-Target” Effect?
Mini-Reviews in Medicinal Chemistry Relationship with Programmed Cell Death Ligand 1 (PD-L1) and DTI Features in Brain Metastases of Non-small Cell Lung Cancer: A Preliminary Study
Current Medical Imaging Identification of HDACs Inhibitor E14 Metabolites Appeared in Rat Plasma, Feces and Urine by UPLC-QTOF-MS/MS
Current Pharmaceutical Analysis Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Matrix Metalloproteinase Inhibitors: A Review on Bioanalytical Methods, Pharmacokinetics and Metabolism
Current Drug Metabolism Tetraketones, Synthesis and their Applications
Current Organic Synthesis Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy The Role Oxidative Stress in the Pathogenesis of Eye Diseases: Currnt Status and a Dual Role of Physical Activity
Mini-Reviews in Medicinal Chemistry Evaluation of Cytotoxic and Tyrosinase Inhibitory Activities of 2-phenoxy(thiomethyl) pyridotriazolopyrimidines: In Vitro and Molecular Docking Studies
Anti-Cancer Agents in Medicinal Chemistry Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Immunotherapy of Melanoma
Current Molecular Pharmacology Autophagy Regulators as Potential Cancer Therapeutic agents: A Review
Current Topics in Medicinal Chemistry Treating Cancer in Older and Oldest Old Patients
Current Pharmaceutical Design Exploring Novel Immunological Interventions Using Immunoinfectomics
Anti-Infective Agents